Compare UIS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UIS | ARMP |
|---|---|---|
| Founded | 1942 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.5M | 199.7M |
| IPO Year | 1994 | 1996 |
| Metric | UIS | ARMP |
|---|---|---|
| Price | $2.21 | $3.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $4.81 | ★ $17.50 |
| AVG Volume (30 Days) | ★ 587.8K | 276.2K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,950,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $3.14 |
| 52 Week High | $4.98 | $14.98 |
| Indicator | UIS | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 38.67 |
| Support Level | $2.14 | $3.38 |
| Resistance Level | $2.61 | $5.63 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 13.55 | 29.41 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.